Devonian Health Group

Devonian Health Group EBITDA per Employee

The EBITDA per Employee of Devonian Health Group (GSD.V) as of Oct 30, 2026 is -76,780.50 CAD. In the previous year, EBITDA per Employee was -51,923.67 CAD — a change of 47.87% (lower).

EBITDA per Employee

-76,780.50CAD

YoY

47.87%

Last updated:

EBITDA per Employee of Devonian Health Group is 2025 -76,780.50 CAD. EBITDA per Employee of Devonian Health Group was 2024 -51,923.67 CAD. It decreases by 47.87% lower compared to the previous year.

The Devonian Health Group EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-472,910.83 CAD
Jan 1, 2019
-531,745.00 CAD
Jan 1, 2020
-679,802.33 CAD
Jan 1, 2021
-376,690.83 CAD
Jan 1, 2022
-440,244.33 CAD
Jan 1, 2023
-672,758.50 CAD
Jan 1, 2024
-51,923.67 CAD
Jan 1, 2025
-76,780.50 CAD
The Devonian Health Group EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-76,780.50CAD+47.87%
-51,923.67CAD-92.28%
-672,758.50CAD+52.81%
-440,244.33CAD+16.87%
-376,690.83CAD-44.59%
-679,802.33CAD+27.84%
-531,745.00CAD+12.44%
-472,910.83CAD+46.27%
-323,308.50CAD+1,024.90%
-28,741.17CAD-90.89%
-315,321.50CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Devonian Health Group Stock analysis

What does Devonian Health Group do? Devonian Health Group Inc develops botanical drugs from plant materials and algae for inflammatory-autoimmune diseases such as ulcerative colitis and atopic dermatitis. The company's flagship product Thykamine, developed through its SUPREX platform, targets inflammation and oxidative stress conditions. Thykamine is distributed through Devonian's subsidiary for pharmaceutical products. The firm also creates value-added dermo-cosmetic products including R-Spinasome and Purgenesis for the cosmeceutical market. Devonian's primary revenue streams come from the development and distribution of botanical pharmaceuticals and dermo-cosmetic products. The company sells Thykamine as a pharmaceutical product for inflammation-related health conditions. R-Spinasome and Purgenesis are sold as cosmeceutical products in the dermo-cosmetic segment. Devonian's subsidiary handles pharmaceutical distribution, generating revenue through this channel. The company focuses on treating inflammatory-autoimmune diseases with its botanical drug development. The company's target customers include patients with inflammatory-autoimmune conditions requiring pharmaceutical treatments and consumers seeking dermo-cosmetic solutions for skin health. Pharmaceutical distributors purchase Thykamine through Devonian's subsidiary. The cosmeceutical market segment buys R-Spinasome and Purgenesis for skin care applications. Devonian's business model centers on developing botanical drugs and value-added products for these specific health and beauty markets. Devonian Health Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Devonian Health Group stock

EBITDA per Employee of Devonian Health Group is -76,780.50 CAD in 2025.

EBITDA per Employee of Devonian Health Group changed from -51,923.67 CAD to -76,780.50 CAD, representing a 47.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Devonian Health Group since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Devonian Health Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Devonian Health Group

All Key Metrics — Devonian Health Group